Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.
Cancer‐specific survival
Circulating tumor cells
Non‐muscle‐invasive bladder cancer
Overall survival
Risk variables
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
15
11
2018
accepted:
31
01
2019
pubmed:
5
4
2019
medline:
12
5
2020
entrez:
5
4
2019
Statut:
ppublish
Résumé
Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis. High-grade T1 (HGT1) bladder cancer is the highest-risk subtype of NMIBC, with an almost 40% rate of recurrence and 20% of progression at 5 years. Nomograms predicting risk of recurrence, progression, and cancer-specific survival (CSS) are not available specifically within HGT1 bladder cancer, and the identification of robust prognostic biomarkers to better guide therapeutic strategies in this subgroup of patients is of paramount importance. Strategies to identify putative biomarkers in liquid biopsies from blood and urine collected from patients with bladder cancer have been intensively studied in the last few years. We here report the final analysis of a single-center prospective study aimed to investigate the impact of circulating tumor cells (CTCs) on CSS and overall survival (OS) in 102 patients with HGT1 bladder cancer, in a median follow-up of 63 months. We here demonstrate that the presence of even a single CTC is predictive of shorter CSS and OS, as compared with the standard predictive variables. Points of attention in this multivariable analysis are the long-term follow-up and the adequate number of outcome events. The accurate risk stratification provided by CTCs might be essential for determining the best surveillance strategy for patients after diagnosis. A closer follow-up, an early radical surgery, or even a systemic treatment might be recommended in patients with super-high-risk non-muscle-invasive bladder cancer. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer who require closer monitoring for local recurrence and/or progression of disease. This super-high-risk subgroup of patients might also require more aggressive treatment interventions, which should be evaluated in large prospective cohorts.
Sections du résumé
BACKGROUND
Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis. High-grade T1 (HGT1) bladder cancer is the highest-risk subtype of NMIBC, with an almost 40% rate of recurrence and 20% of progression at 5 years. Nomograms predicting risk of recurrence, progression, and cancer-specific survival (CSS) are not available specifically within HGT1 bladder cancer, and the identification of robust prognostic biomarkers to better guide therapeutic strategies in this subgroup of patients is of paramount importance. Strategies to identify putative biomarkers in liquid biopsies from blood and urine collected from patients with bladder cancer have been intensively studied in the last few years.
SUBJECTS, MATERIALS, AND METHODS
We here report the final analysis of a single-center prospective study aimed to investigate the impact of circulating tumor cells (CTCs) on CSS and overall survival (OS) in 102 patients with HGT1 bladder cancer, in a median follow-up of 63 months.
RESULTS
We here demonstrate that the presence of even a single CTC is predictive of shorter CSS and OS, as compared with the standard predictive variables. Points of attention in this multivariable analysis are the long-term follow-up and the adequate number of outcome events.
CONCLUSION
The accurate risk stratification provided by CTCs might be essential for determining the best surveillance strategy for patients after diagnosis. A closer follow-up, an early radical surgery, or even a systemic treatment might be recommended in patients with super-high-risk non-muscle-invasive bladder cancer.
IMPLICATIONS FOR PRACTICE
Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer who require closer monitoring for local recurrence and/or progression of disease. This super-high-risk subgroup of patients might also require more aggressive treatment interventions, which should be evaluated in large prospective cohorts.
Identifiants
pubmed: 30944184
pii: theoncologist.2018-0784
doi: 10.1634/theoncologist.2018-0784
pmc: PMC6516110
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-616Informations de copyright
© AlphaMed Press 2019.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Clin Cancer Res. 2017 Nov 1;23(21):6487-6497
pubmed: 28760909
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Adv Drug Deliv Rev. 2018 Feb 1;125:102-121
pubmed: 29355669
Nat Rev Urol. 2019 Jan;16(1):23-34
pubmed: 30323201
Transl Androl Urol. 2017 Dec;6(6):1198-1202
pubmed: 29354512
Bladder Cancer. 2015 Sep 5;2(1):1-14
pubmed: 27376120
Curr Urol Rep. 2018 Oct 26;19(12):103
pubmed: 30367268
Int J Cancer. 2014 Oct 15;135(8):1978-82
pubmed: 24599551
World J Urol. 2019 Jan;37(1):31-40
pubmed: 30259123
J Clin Oncol. 2015 Feb 20;33(6):643-50
pubmed: 25559810
Clin Cancer Res. 2018 Apr 1;24(7):1586-1593
pubmed: 29367430
Curr Urol Rep. 2018 Oct 24;19(12):101
pubmed: 30357541
Methods Mol Biol. 2015;1347:263-78
pubmed: 26374323
Oncotarget. 2017 Jun 16;8(35):59527-59538
pubmed: 28938656